PMID- 30230959
OWN - NLM
STAT- MEDLINE
DCOM- 20200212
LR  - 20200309
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 15
IP  - 2
DP  - 2019
TI  - Long-term survival of pancreatic cancer patients treated with multimodal therapy 
      combined with WT1-targeted dendritic cell vaccines.
PG  - 397-406
LID - 10.1080/21645515.2018.1524238 [doi]
AB  - BACKGROUND/AIM: Pancreatic ductal adenocarcinoma (PDA) remains one of the most 
      aggressive tumors with a dismally poor prognosis. Although surgical resection 
      remains the only potentially curative treatment, most PDAs are not surgically 
      resectable at diagnosis. Therefore, multimodal therapy is urgently needed to 
      improve the long-term survival of PDA patients. METHODS: Six eligible PDA 
      patients underwent multimodal therapy comprising dendritic cells (DCs) pulsed 
      with Wilms' tumor 1 (WT1) peptide (DC/WT1-I) restricted by the human leukocyte 
      antigen (HLA) class I (A*24:02 or A*02:06) allele, chemotherapy, radiation, 
      and/or surgery. Patient laboratory data, DC/WT1-I-specific delayed-type 
      hypersensitivity (DTH) reactions, and WT1-specific immune responses were analyzed 
      to assess the prognostic markers of multimodal therapy. RESULTS: Compared to 
      2-treatment type combinations, multimodal therapy involving 3 to 4 treatment 
      types was significantly associated with longer overall survival (p = 0.0177). 
      Moreover, after 7 DC/WT1-I vaccinations, the progression-free survival (PFS) of 
      PDA patients with a neutrophil to lymphocyte ratio (NLR) or C-reactive protein 
      (CRP) level less than the median was superior to that of PDA patients with values 
      above the median (p = 0.0246). PDA patients with an overall survival 
      (OS)>1000 days had significantly more lymphocytes after one DC/WT1-I vaccination 
      course than did those with an OS<1000 days. CONCLUSION: Multimodal therapy 
      involving the DC/WT1-I vaccination may benefit patients with advanced PDA. 
      However, comparing the limited number of PDA patients in terms of survival is 
      difficult because the patients were at different disease stages and received 
      different treatments. Further studies are needed to evaluate the clinical 
      benefits of this multimodal therapy.
FAU - Hanada, Shuichi
AU  - Hanada S
AD  - a Department of Hematology , National Hospital Organization Kagoshima Medical 
      Center , Kagoshima , Japan.
FAU - Tsuruta, Tomoko
AU  - Tsuruta T
AD  - a Department of Hematology , National Hospital Organization Kagoshima Medical 
      Center , Kagoshima , Japan.
FAU - Haraguchi, Kouichi
AU  - Haraguchi K
AD  - a Department of Hematology , National Hospital Organization Kagoshima Medical 
      Center , Kagoshima , Japan.
FAU - Okamoto, Masato
AU  - Okamoto M
AD  - b Department of Advanced Immunotherapeutics, Graduate School of Pharmaceutical 
      Sciences , Osaka University , Suita , Osaka , Japan.
FAU - Sugiyama, Haruo
AU  - Sugiyama H
AD  - c Department of Functional Diagnostic Science , Osaka University Graduate School 
      of Medicine , Suita , Osaka , Japan.
FAU - Koido, Shigeo
AU  - Koido S
AD  - d Division of Gastroenterology and Hepatology, Department of Hematology , The 
      Jikei University School of Medicine , Kashiwa City , Chiba , Japan.
AD  - e Institute of Clinical Medicine and Research , The Jikei University School of 
      Medicine , Kashiwa City , Chiba , Japan.
LA  - eng
PT  - Journal Article
DEP - 20181012
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA Antigens)
RN  - 0 (WT1 Proteins)
SB  - IM
MH  - Aged
MH  - Cancer Vaccines/*therapeutic use
MH  - Carcinoma, Pancreatic Ductal/*immunology/*therapy
MH  - Combined Modality Therapy
MH  - Dendritic Cells/*immunology
MH  - Disease Progression
MH  - Female
MH  - HLA Antigens/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Survivors
MH  - WT1 Proteins/*immunology
PMC - PMC6422489
OTO - NOTNLM
OT  - WT1
OT  - dendritic cell
OT  - multimodal therapy
OT  - pancreatic cancer
OT  - vaccine
EDAT- 2018/09/20 06:00
MHDA- 2020/02/13 06:00
PMCR- 2019/10/12
CRDT- 2018/09/20 06:00
PHST- 2018/09/20 06:00 [pubmed]
PHST- 2020/02/13 06:00 [medline]
PHST- 2018/09/20 06:00 [entrez]
PHST- 2019/10/12 00:00 [pmc-release]
AID - 1524238 [pii]
AID - 10.1080/21645515.2018.1524238 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2019;15(2):397-406. doi: 10.1080/21645515.2018.1524238. 
      Epub 2018 Oct 12.